Ticlopidine-induced aplastic anemia: Development of chromosomal abnormalities and response to immunosuppressive therapy

✍ Scribed by Pullarkat, Vinod A.; Rho, Hyan; Murata-Collins, Joyce L.; Liebman, Howard A.

• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: English
• Weight: 49 KB
• Volume: 63
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/(sici)1096-8652(200003)63:3<141::aid-ajh6>3.0.co;2-t

✦ Synopsis

Severe aplastic anemia is a well-recognized complication of ticlopidine therapy that carries a high mortality. Therapy with colony-stimulating factors or corticosteroids has been largely ineffective in this disorder. We report a case of ticlopidine-induced aplastic anemia that was successfully treated with cyclosporine and high-dose dexamethasone. The patient rapidly responded to immunosuppressive therapy and had a normal hemogram after cessation of immunosuppression. On long-term follow-up, the patient developed a progressive macrocytic anemia. Repeat bone marrow evaluation demonstrated myelodysplasia with erythroid hypoplasia. An associated chromosomal abnormality consisting of a t(3;16) (q21; p13.3) translocation was detected. This is the first report of a chromosomal abnormality associated with ticlopidine induced marrow aplastic anemia. Am.